TY - JOUR
T1 - The effect of small doses of fructose and allulose on postprandial glucose metabolism in type 2 diabetes
T2 - A double-blind, randomized, controlled, acute feeding, equivalence trial
AU - Noronha, Jarvis C.
AU - Braunstein, Catherine R.
AU - Glenn, Andrea J.
AU - Khan, Tauseef A.
AU - Viguiliouk, Effie
AU - Noseworthy, Rebecca
AU - Blanco Mejia, Sonia
AU - Kendall, Cyril W.C.
AU - Wolever, Thomas M.S.
AU - Leiter, Lawrence A.
AU - Sievenpiper, John L.
N1 - Publisher Copyright:
© 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
PY - 2018/10
Y1 - 2018/10
N2 - Aim: To assess and compare the effect of small doses of fructose and allulose on postprandial blood glucose regulation in type 2 diabetes. Methods: A double-blind, multiple-crossover, randomized, controlled, acute feeding, equivalence trial in 24 participants with type 2 diabetes was conducted. Each participant was randomly assigned six treatments separated by >1-week washouts. Treatments consisted of fructose or allulose at 0 g (control), 5 g or 10 g added to a 75-g glucose solution. A standard 75-g oral glucose tolerance test protocol was followed with blood samples at −30, 0, 30, 60, 90 and 120 minutes. The primary outcome measure was plasma glucose incremental area under the curve (iAUC). Results: Allulose significantly reduced plasma glucose iAUC by 8% at 10 g compared with 0 g (717.4 ± 38.3 vs. 777.5 ± 39.9 mmol × min/L, P = 0.015) with a linear dose response gradient between the reduction in plasma glucose iAUC and dose (P = 0.016). Allulose also significantly reduced several related secondary and exploratory outcome measures at 5 g (plasma glucose absolute mean and total AUC) and 10 g (plasma glucose absolute mean, absolute and incremental maximum concentration [Cmax], and total AUC) (P <.0125). There was no effect of fructose at any dose. Although allulose showed statistically significant reductions in plasma glucose iAUC compared with fructose at 5 g, 10 g and pooled doses, these reductions were within the pre-specified equivalence margins of ±20%. Conclusion: Allulose, but not fructose, led to modest reductions in the postprandial blood glucose response to oral glucose in individuals with type 2 diabetes. There is a need for long-term randomized trials to confirm the sustainability of these improvements.
AB - Aim: To assess and compare the effect of small doses of fructose and allulose on postprandial blood glucose regulation in type 2 diabetes. Methods: A double-blind, multiple-crossover, randomized, controlled, acute feeding, equivalence trial in 24 participants with type 2 diabetes was conducted. Each participant was randomly assigned six treatments separated by >1-week washouts. Treatments consisted of fructose or allulose at 0 g (control), 5 g or 10 g added to a 75-g glucose solution. A standard 75-g oral glucose tolerance test protocol was followed with blood samples at −30, 0, 30, 60, 90 and 120 minutes. The primary outcome measure was plasma glucose incremental area under the curve (iAUC). Results: Allulose significantly reduced plasma glucose iAUC by 8% at 10 g compared with 0 g (717.4 ± 38.3 vs. 777.5 ± 39.9 mmol × min/L, P = 0.015) with a linear dose response gradient between the reduction in plasma glucose iAUC and dose (P = 0.016). Allulose also significantly reduced several related secondary and exploratory outcome measures at 5 g (plasma glucose absolute mean and total AUC) and 10 g (plasma glucose absolute mean, absolute and incremental maximum concentration [Cmax], and total AUC) (P <.0125). There was no effect of fructose at any dose. Although allulose showed statistically significant reductions in plasma glucose iAUC compared with fructose at 5 g, 10 g and pooled doses, these reductions were within the pre-specified equivalence margins of ±20%. Conclusion: Allulose, but not fructose, led to modest reductions in the postprandial blood glucose response to oral glucose in individuals with type 2 diabetes. There is a need for long-term randomized trials to confirm the sustainability of these improvements.
KW - clinical trial
KW - dietary intervention
KW - dose–response relationship
KW - glucose
KW - metabolism
KW - randomized trial
KW - type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85053075902&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053075902&partnerID=8YFLogxK
U2 - 10.1111/dom.13374
DO - 10.1111/dom.13374
M3 - Article
C2 - 29797503
AN - SCOPUS:85053075902
SN - 1462-8902
VL - 20
SP - 2361
EP - 2370
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
IS - 10
ER -